Cancer gene therapy - Cell Genesys/EntreMed

Drug Profile

Cancer gene therapy - Cell Genesys/EntreMed

Alternative Names: Angiogenesis inhibitor gene therapy - Cell Genesys/EntreMed; Angiostatin/endostatin gene therapy - Cell Genesys/EntreMed

Latest Information Update: 13 Aug 2003

Price : $50

At a glance

  • Originator Cell Genesys; EntreMed
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 25 Nov 2002 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 21 Jun 2002 Preliminary preclinical study results have been added to the pharmacodynamics section
  • 05 Mar 2001 Profile reviewed but no significant changes made
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top